3/4
05:22 pm
pasg
Passage Bio, Inc. (NASDAQ: PASG) had its price target lowered by analysts at Chardan Capital from $7.00 to $6.00. They now have a "buy" rating on the stock.
Medium
Report
Passage Bio, Inc. (NASDAQ: PASG) had its price target lowered by analysts at Chardan Capital from $7.00 to $6.00. They now have a "buy" rating on the stock.
3/4
08:05 am
pasg
Passage Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Recent Business Highlights [Yahoo! Finance]
High
Report
Passage Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Recent Business Highlights [Yahoo! Finance]
3/4
07:00 am
pasg
Passage Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Recent Business Highlights
High
Report
Passage Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Recent Business Highlights
2/26
07:00 am
pasg
Passage Bio to Participate in Upcoming Investor Conferences
Medium
Report
Passage Bio to Participate in Upcoming Investor Conferences
1/10
07:00 am
pasg
Passage Bio Announces Interim Data from upliFT-D Study in FTD-GRN and Provides Business Updates
Medium
Report
Passage Bio Announces Interim Data from upliFT-D Study in FTD-GRN and Provides Business Updates